Showing results (61-70 of 188) with videos related to

Sort By:
Pageof 19
Trials|February 15, 2020
Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)Ruth Nabisere, Joseph Musaazi, Paolo Denti, et al.
BMC Health Services Research|August 3, 2020
Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and UgandaYussif Alhassan, Adelline Twimukye, Thoko Malaba, et al.
The Journal of Antimicrobial Chemotherapy|September 22, 2018
High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatmentAmrei von Braun, Barbara Castelnuovo, Bruno Ledergerber, et al.
The American Journal of Tropical Medicine and Hygiene|February 18, 2025
Cleaning and Disinfection Practices of Reused Alcohol-Based Hand Rub Containers in Health Care Settings: Evidence from Five Rural Districts in UgandaFred Tusabe, Kanako Ishida, Francis Ocitti, et al.
BMC Infectious Diseases|March 27, 2019
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavirEva Agnes Odongpiny Laker, Maria Sarah Nabaggala, Arvind Kaimal, et al.
African Health Sciences|November 2, 2022
Support for the response to COVID-19 in Uganda: contribution of the global health security program at Makerere University's Infectious Diseases InstituteMohammed Lamorde, Rodgers Ayebare, Daniel Bulwadda, et al.
BMC Public Health|December 8, 2020
Community acceptability of dolutegravir-based HIV treatment in women: a qualitative study in South Africa and UgandaYussif Alhassan, Adelline Twimukye, Thoko Malaba, et al.
Tuberculosis (Edinburgh, Scotland)|March 11, 2018
The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugsChristine Sekaggya-Wiltshire, Mohammed Lamorde, Agnes N Kiragga, et al.
Clinical Pharmacology and Therapeutics|February 20, 2019
The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH StudyAndrea Calcagno, Jessica Cusato, Christine Sekaggya-Wiltshire, et al.
Wellcome Open Research|January 31, 2019
Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infectionJayne Ellis, Prosperity C Eneh, Kenneth Ssebambulidde, et al.
Pageof 19